Aviv Scientific
Cognitive and Functional Decline Treatment Solutions
Company Overview
Snapshot
Founded in July 2017 by Shai Efrati, Jonathan Preminger, and Michael Lobel, Aviv Scientific operates with 11–50 employees. The company has raised $62 million across two funding rounds from three investors. In September 2021, Aviv Scientific secured a significant funding round.
Business overview
Aviv Scientific specializes in addressing age-related cognitive and functional decline through novel applications of hyperbaric medicine. The company's core offering, the Aviv Medical Program, combines unique hyperbaric oxygen therapy (HBOT) protocols with personalized cognitive and physical training. Aviv Scientific serves the health tech and life sciences markets, focusing on enhancing cognitive and physical performance in healthy aging adults and operating a global network of medical clinics in sectors including digital healthcare, digital therapeutics, and medical data.
Strategic signal
In March 2023, Aviv Clinics highlighted a new hyperbaric oxygen therapy study, bringing hope to fibromyalgia patients. This signals the company's ongoing commitment to clinical research and its potential to expand the application of its hyperbaric medicine protocols to new patient populations, validating its scientific approach and market relevance.
Company Intelligence Q&A
- What is Aviv Scientific's primary focus?
- Aviv Scientific focuses on treating age-related cognitive and functional decline by applying novel hyperbaric medicine techniques to maximize human performance and improve the aging process.
- When was Aviv Scientific founded and by whom?
- Aviv Scientific was founded in July 2017 by Shai Efrati, Jonathan Preminger, and Michael Lobel.
- What is the Aviv Medical Program?
- The Aviv Medical Program combines unique protocols of hyperbaric oxygen therapy (HBOT) with a proprietary personalized program of cognitive and physical training, designed to enhance cognitive and physical performance.
- How much capital has Aviv Scientific raised?
- Aviv Scientific has raised a total of $62 million across two funding rounds.
- What significant research was highlighted by Aviv Clinics in March 2023?
- In March 2023, Aviv Clinics highlighted a new study demonstrating the potential of hyperbaric oxygen therapy to bring hope to fibromyalgia patients.